Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities

Nastran Hashemzadeh ^1,2, Khosro Adibkia ^1,3 , Jaleh Barar ^1,3 *

Cited by CrossRef: 2

1- Martynchyk A, Chowdhury R, Hawkes E, Keane C. Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma. Cancers. 2023;15(21):5217 [Crossref]

2- Zhou Y, Wang H, Luo Y, Tuo B, Liu X, Li T. Effect of metabolism on the immune microenvironment of breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(2):188861 [Crossref]

3- Shim N, Cho H, Jeon S, Kim K. Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy. J Pharm Investig. 2024;54(1):13 [Crossref]

4- Hashemzadeh N, Dolatkhah M, Aghanejad A, Barzegar-Jalali M, Omidi Y, Adibkia K, Barar J. Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells. Nanomedicine. 2021;16(24):2137 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons